CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma
January 28, 2021
0
CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals (CASI) partner BioInvent International (